First-in-Class Pipeline of Multi-Target Antibody Therapies For Immunology, Accelerated by AI
At CoFormBio, we will have in the clinic co-formulated antibody therapeutics, guided by CoForm Forge™, our advanced, deep learning AI engine.
Experience Breakthrough Therapies and Rapid Results
Discover how CoFormBio’s co-formulated antibodies transform immunology treatments, delivering faster clinical proof-of-concept and enhanced patient outcomes.
- Dual-target therapies that enhance treatment efficacy
- Redeployment of clinical-stage biologics for quicker development
- Innovative co-formulation techniques ensuring fixed-dose convenience
- Focused immunology solutions addressing unmet medical needs
Innovating Dual-Target Antibody Therapies
Explore our breakthrough data demonstrating rapid clinical proof-of-concept and enhanced treatment efficacy.
45
Evaluating Clinical Programs
Leveraging co-formulated antibodies to accelerate immunology therapy development with proven clinical-stage biologics.
8
Term Sheets
In term sheet stage for 8 clinical stage prorgams – expected to close in Q4 ’26 or Q1 ’27
Innovating Dual-Target Antibody Therapies for Immunology
Discover our breakthrough co-formulated antibody therapies designed to accelerate clinical success and improve patient outcomes.
Our Approach
Discover how CoFormBio combines advanced antibody co-formulation to accelerate development and enhance treatment efficacy.
Step One: Antibody Selection
Identify and select complementary clinical-stage antibodies to formulate dual-target therapies optimized for immunology – guided by CoForm Forge™, our advanced, deep learning AI engine.
Step Two: Co-Formulation
Expertly combine antibodies into fixed-dose formats, ensuring stability and synergistic activity for rapid clinical impact.
Step Three: Clinical Proof
Advance the co-formulated therapy through proof-of-concept trials to demonstrate superior efficacy and safety.
Pioneering Dual-Target Antibody Therapies
+1-617-555-0198
rajeev@coform.bio or sam.davis@coform.bio